285124-45-0 Usage
General Description
3-Isobutylamino-propan-1-ol is a chemical compound that is also known as ibutolol. It is a beta-adrenergic blocking agent that affects the heart and circulation in the body. 3-ISOBUTYLAMINO-PROPAN-1-OL is commonly used to treat high blood pressure and heart failure. It works by relaxing blood vessels and slowing the heart rate to improve blood flow and decrease blood pressure. This chemical is often found in medication formulations and should be used under the supervision of a healthcare professional. It is important to follow the prescribed dosage and guidelines for the safe and effective use of 3-isobutylamino-propan-1-ol.
Check Digit Verification of cas no
The CAS Registry Mumber 285124-45-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,5,1,2 and 4 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 285124-45:
(8*2)+(7*8)+(6*5)+(5*1)+(4*2)+(3*4)+(2*4)+(1*5)=140
140 % 10 = 0
So 285124-45-0 is a valid CAS Registry Number.
InChI:InChI=1/C7H17NO/c1-7(2)6-8-4-3-5-9/h7-9H,3-6H2,1-2H3/p+1
285124-45-0Relevant articles and documents
METHOD OF PRODUCING N-ALKYL POLYAMINES
-
Page/Page column 20, (2016/03/22)
In one embodiment, the invention presents a process for the preparation of N-alkyl polyamines that includes (i) the conversion of an amino alcohol to an aminoalkyl alkylating agent with a halo or aldehyde reactive group and (ii) the addition of amines to an aminecontaining alkylating agent to make an N-alkyl polyamine.
Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
-
Page column 44, (2010/02/05)
This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.
